A Novel Class of Antibiotics Targeting Highly Resistant Bacteria
|PRODUCT/INDICATION||PRE CLINICAL||PHASE 1||PHASE 2||PHASE 3|
|ESKAPE Pathogen Program|
ESKAPE: The ESKAPE pathogen is methicillin-resistant Staphylococcus aureus
In addition to our late stage portfolio, we have an active research platform based on Nobel Prize-winning science and a powerful, proprietary drug discovery platform. In our ESKAPE Pathogen Program, we are focused on developing breakthrough antibiotics for bacterial “superbugs”. ESKAPE pathogens include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli.
Our goal is to introduce completely novel classes of antibiotics to meet the challenge posed by the alarming emergence of bacteria that have developed resistance to all existing drug classes. Currently these pathogens cause mortality rates approaching 50 percent in some infection types, making “superbugs” the most serious hospital-treated bacterial threat. In addition, the causative pathogen is often unknown, creating the need for therapies that cover the full range of potential bacteria.
We have successfully designed three novel classes of antibiotics that show potent activity in the laboratory and in animal infection models. In our lead class, known as the pyrrolocytosines, several compounds have demonstrated comprehensive activity across the full set of bacterial “superbugs.” We believe this new class of antibiotic could be transformational in the fight against this urgent threat. Based on significant recent progress, our ESKAPE Pathogen Program is poised to deliver compounds to enter development in 2016 for advancement to human clinical trials in 2017.
Click here to visit the ESKAPE Pathogen Program Publications webpage.